ArticleThe journal of medicine access
Sphenopalatine ganglion (SPG) blocks: Evidence and implementation for acute migraine treatment in the primary care setting.
Article in The journal of medicine access. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Sphenopalatine Ganglion Blocks in Headache Management: A Review.Brain sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sphenopalatine ganglion (SPG) blocks may be effective and affordable treatments for acute migraine but are rarely used in the primary care setting, making them inaccessible treatment for those suffering from migraine. Objective: To outline evidence for the use of SPG block in the treatment of acute migraine. To determine the feasibility and effectiveness of primary care in-office and at-home SPG block administration. Methods: A retrospective chart review of patients receiving in-office or at-home SPG block to treat acute migraine was completed. Pre- and post-treatment pain measurements were the primary outcome, along with patient-reported adverse effects. Results: Results from this study revealed that 87% of SPG block administrations (via catheter and atomizer) resulted in pain relief with minimal adverse effects. Methods and materials for catheter and atomizer administration of SPG blocks are outlined, in addition to tips for integrating this service into primary care practices. Conclusions: This study showed that SPG blocks may be administered effectively in primary care settings or at home with proper patient education and are an effective treatment modality to decrease pain associated with acute migraine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.